Flagship Ventures Fund V, L.P. 13D and 13G filings for Denali Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-16 5:08 pm Sale | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | Flagship Ventures Fund V, L.P. | 2,730,263 2.200% | -5,250,000 (-65.79%) | Filing |
| 2020-02-13 4:18 pm Sale | 2019-12-31 | 13G | Denali Therapeutics Inc. DNLI | Flagship Ventures Fund V, L.P. | 7,980,263 8.300% | -938,486 (-10.52%) | Filing |